Jnana Therapeutics
Jnana Therapeutics develops small molecule medicines using the RAPID platform, focusing on therapies for phenylketonuria (PKU) and immune-mediated diseases.
Services
Jnana Therapeutics develops small molecule medicines leveraging their proprietary RAPID platform. The platform enables the systematic development of small molecule treatments for any target class, enhancing speed and efficiency. Utilizing next-generation chemoproteomics, Jnana Therapeutics uncovers unique binding sites on highly validated protein targets. Their services focus on the rapid advancement of therapies for diseases with high unmet medical needs, including rare and immune-mediated diseases.
Therapies for Phenylketonuria (PKU)
Jnana Therapeutics is advancing first-in-class therapies to treat phenylketonuria (PKU). Their lead clinical candidate, JNT-517, is an oral treatment targeting a cryptic, allosteric site on the SLC6A19 transporter to reduce plasma phenylalanine levels. JNT-517 is currently undergoing clinical trials, including a Phase 1b trial for individuals with PKU. The U.S. Food and Drug Administration granted JNT-517 Rare Pediatric Disease Designation in late 2022.
RAPID Platform
The RAPID platform is Jnana Therapeutics' proprietary technology for developing small molecule medicines. This platform allows for the systematic creation of treatments for any target class, improving the speed and efficiency of the drug development process. By utilizing next-generation chemoproteomics, RAPID helps identify unique binding sites on highly validated protein targets. This innovative platform underpins Jnana’s efforts to address diseases with significant unmet medical needs.
Focus Areas
Jnana Therapeutics focuses on developing therapies for diseases with high unmet medical needs. Their primary areas include rare diseases such as phenylketonuria (PKU) and a broad range of immune-mediated diseases. Through their innovative RAPID platform, Jnana Therapeutics is able to uncover unique druggable sites and advance first- and best-in-class therapies quickly and efficiently.
Clinical Trials
Jnana Therapeutics is conducting clinical trials for their lead candidate, JNT-517, aimed at treating phenylketonuria (PKU). These trials include a Phase 1b trial specifically targeting individuals affected by PKU. The clinical research focuses on assessing the safety and efficacy of JNT-517, a small molecule medicine designed to reduce plasma phenylalanine levels by targeting a cryptic, allosteric site on the SLC6A19 transporter.
